References
- Hall-FlavinDKWinnerJGAllenJDUsing a pharmacogenomic algorithm to guide the treatment of depressionTransl Psychiatry20122e17223047243
- Hall-FlavinDKWinnerJGAllenJDUtility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenet Genomics2013231053554824018772
- WinnerJGCarhartJMAltarCAAllenJDDechairoBMA prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorderDiscov Med2013168921922724229738
- AltarCACarhartJMAllenJDHall-FlavinDKDechairoBMWinnerJGClinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypesPharmacogenomics J201515544345125686762
- MrazekDAPsychiatric PharmacogenomicsOxford University Press2010
- INVEGA® (paliperidone) extended-release tablets [package insert]Titusville, NJJanssen Pharmaceuticals2015
- SuzukiHGenKInoueYThe influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trialInt J Psychiatry Clin Pract2014181586224047427
- AltamuraACSassellaFSantiniAMontresorCFumagalliSMundoEIntramuscular preparations of antipsychotics: uses and relevance in clinical practiceDrugs200363549351212600227
- ChoongEPolariAKamdemRHPharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effectsJ Clin Psychopharmacol201333328929823609392
- LaneHYChangYCChiuCCChenMLHsiehMHChangWHAssociation of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor geneAm J Psychiatry200215991593159512202283
- YamanouchiYIwataNSuzukiTKitajimaTIkedaMOzakiNEffect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidonePharmacogenomics J20033635636114610521
- AleniusMWadeliusMDahlM-LHartvigPLindströmLHammarlund- UdenaesMGene polymorphism influencing treatment response in psychotic patients in a naturalistic settingJ Psychiatr Res2008421188489318086475
- IkedaMYamanouchiYKinoshitaYVariants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophreniaPharmacogenomics20089101437144318855532
- KimBChoiEYKimCYSongKJooYHCould HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic settingHum Psychopharmacol2008231616717924589
- AngelucciFBernardiniSGravinaPDelusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer’s disease: a 3-year follow-up longitudinal studyJ Alzheimers Dis200917120321119494443
- WinnerJLorenzRAAllenJDCarhartJMDechairoBMHealth Care Utilization and Medication Cost Savings in Patients Receiving Combinatorial Psychiatric Pharmacogenomic TestingPoster presented at: American Psychiatric Association Annual MeetingMay 18, 2015Toronto, ON